Cabaletta Bio Inc
CABA2.390USD
0.000
Close 12/22, 16:00（ET）Quotes delayed by 15 min
230.07MMarket Cap
LossP/E TTM
More Details of Cabaletta Bio Inc Company
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Cabaletta Bio Inc Info
Ticker SymbolCABA
Company nameCabaletta Bio Inc
IPO dateOct 25, 2019
CEONichtberger (Steven)
Number of employees161
Security typeOrdinary Share
Fiscal year-endOct 25
Address2929 Arch Street
CityPHILADELPHIA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19104
Phone12677593100
Websitehttps://www.cabalettabio.com/
Ticker SymbolCABA
IPO dateOct 25, 2019
CEONichtberger (Steven)
Company Executives of Cabaletta Bio Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Steven Nichtberger, M.D.
Dr. Steven Nichtberger, M.D.
Chief Executive Officer, President, Chairman of the Board, Co-Founder
Chief Executive Officer, President, Chairman of the Board, Co-Founder
1.35M
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Dr. David J. Chang, M.D.
Dr. David J. Chang, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Catherine Bollard, M.D.
Dr. Catherine Bollard, M.D.
Independent Director
Independent Director
--
--
Mr. Mark J. Simon
Mr. Mark J. Simon
Independent Director
Independent Director
--
--
Ms. Shawn Cline Tomasello
Ms. Shawn Cline Tomasello
Independent Director
Independent Director
--
--
Mr. Richard Conover Henriques, Jr.
Mr. Richard Conover Henriques, Jr.
Independent Director
Independent Director
--
--
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
President - Science and Technology
President - Science and Technology
--
--
Dr. Arun Das, M.D.
Dr. Arun Das, M.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Anup Marda
Mr. Anup Marda
Chief Financial Officer
Chief Financial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Steven Nichtberger, M.D.
Dr. Steven Nichtberger, M.D.
Chief Executive Officer, President, Chairman of the Board, Co-Founder
Chief Executive Officer, President, Chairman of the Board, Co-Founder
1.35M
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Dr. David J. Chang, M.D.
Dr. David J. Chang, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Catherine Bollard, M.D.
Dr. Catherine Bollard, M.D.
Independent Director
Independent Director
--
--
Mr. Mark J. Simon
Mr. Mark J. Simon
Independent Director
Independent Director
--
--
Ms. Shawn Cline Tomasello
Ms. Shawn Cline Tomasello
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
T. Rowe Price Investment Management, Inc.
10.76%
Bain Capital Life Sciences Investors, LLC
10.05%
Adage Capital Management, L.P.
9.17%
Jennison Associates LLC
8.83%
Cormorant Asset Management, LP
5.19%
Other
55.99%
Shareholders
Shareholders
Proportion
T. Rowe Price Investment Management, Inc.
10.76%
Bain Capital Life Sciences Investors, LLC
10.05%
Adage Capital Management, L.P.
9.17%
Jennison Associates LLC
8.83%
Cormorant Asset Management, LP
5.19%
Other
55.99%
Shareholder Types
Shareholders
Proportion
Investment Advisor
33.49%
Hedge Fund
24.46%
Investment Advisor/Hedge Fund
14.01%
Research Firm
1.90%
Individual Investor
1.57%
Venture Capital
0.30%
Bank and Trust
0.04%
Other
24.23%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
332
71.53M
101.82%
+2.00M
2025Q3
342
69.53M
105.84%
-3.44M
2025Q2
342
72.97M
65.79%
+36.49M
2025Q1
337
36.48M
122.66%
-25.76M
2024Q4
337
38.65M
120.50%
-4.03M
2024Q3
325
48.73M
125.05%
-4.12M
2024Q2
319
51.66M
131.37%
-2.68M
2024Q1
305
51.55M
117.43%
-5.10M
2023Q4
264
49.06M
116.05%
+7.90M
2023Q3
238
41.02M
113.84%
+4.24M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
T. Rowe Price Investment Management, Inc.
6.79M
7.43%
+2.82M
+71.13%
Jun 30, 2025
Bain Capital Life Sciences Investors, LLC
9.68M
10.58%
+6.92M
+250.51%
Jun 30, 2025
Adage Capital Management, L.P.
8.83M
9.65%
+5.20M
+142.94%
Jun 30, 2025
Jennison Associates LLC
6.02M
6.58%
+3.59M
+147.36%
Jun 30, 2025
Cormorant Asset Management, LP
5.00M
5.47%
+5.00M
--
Jun 30, 2025
The Vanguard Group, Inc.
3.45M
3.77%
+606.49K
+21.32%
Jun 30, 2025
Woodline Partners LP
1.22M
1.33%
+1.22M
--
Jun 30, 2025
Heights Capital Management, Inc.
3.14M
3.44%
+3.14M
--
Jun 30, 2025
Superstring Capital Management LP
1.06M
1.16%
+601.79K
+131.12%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
887.27K
0.97%
-2.22M
-71.43%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.06%
Avantis US Small Cap Equity ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Humankind US Stock ETF
0%
ProShares UltraPro Russell2000
0%
Optimize Strategy Index ETF
0%
Alger 35 ETF
0%
iShares Russell 2000 Value ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.06%
Avantis US Small Cap Equity ETF
Proportion0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
Humankind US Stock ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Optimize Strategy Index ETF
Proportion0%
Alger 35 ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Invesco Nasdaq Biotechnology ETF
Proportion0%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Cabaletta Bio Inc?
The top five shareholders of Cabaletta Bio Inc are:
T. Rowe Price Investment Management, Inc. holds 6.79M shares, accounting for 7.43% of the total shares.
Bain Capital Life Sciences Investors, LLC holds 9.68M shares, accounting for 10.58% of the total shares.
Adage Capital Management, L.P. holds 8.83M shares, accounting for 9.65% of the total shares.
Jennison Associates LLC holds 6.02M shares, accounting for 6.58% of the total shares.
Cormorant Asset Management, LP holds 5.00M shares, accounting for 5.47% of the total shares.
T. Rowe Price Investment Management, Inc. holds 6.79M shares, accounting for 7.43% of the total shares.
Bain Capital Life Sciences Investors, LLC holds 9.68M shares, accounting for 10.58% of the total shares.
Adage Capital Management, L.P. holds 8.83M shares, accounting for 9.65% of the total shares.
Jennison Associates LLC holds 6.02M shares, accounting for 6.58% of the total shares.
Cormorant Asset Management, LP holds 5.00M shares, accounting for 5.47% of the total shares.
What are the top three shareholder types of Cabaletta Bio Inc?
The top three shareholder types of Cabaletta Bio Inc are:
T. Rowe Price Investment Management, Inc.
Bain Capital Life Sciences Investors, LLC
Adage Capital Management, L.P.
T. Rowe Price Investment Management, Inc.
Bain Capital Life Sciences Investors, LLC
Adage Capital Management, L.P.
How many institutions hold shares of Cabaletta Bio Inc (CABA)?
As of 2025Q4, 332 institutions hold shares of Cabaletta Bio Inc, with a combined market value of approximately 71.53M, accounting for 101.82% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -4.02%.
What is the biggest source of revenue for Cabaletta Bio Inc?
In --, the -- business generated the highest revenue for Cabaletta Bio Inc, amounting to -- and accounting for --% of total revenue.
